Buy Tirzepatide 10mg: Dual GIP/GLP-1 Agonist for Metabolic Research

Tirzepatide (10mg) is a synthetic dual GIP and GLP-1 receptor agonist extensively studied for its effects on type 2 diabetes and obesity. Research, including pivotal SURPASS and SURMOUNT trials, highlights its role in improving insulin sensitivity, regulating appetite, supporting substantial weight loss, and providing potential cardiovascular benefits. This research-grade peptide, supplied in a 10mg vial with 99% purity, is ideal for investigating incretin-based mechanisms, dose-response effects, glycemic control, and body composition in experimental models.

Molecular Formula: C225H348N48O68 Molecular Weight: 4813.527 g/mol Purity: 99%

Important Notice: These peptides are strictly intended for research and laboratory use only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Please review and agree to our Terms and Conditions before placing an order.

What is Tirzepatide?

Tirzepatide is a 39-amino-acid polypeptide engineered as a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action differentiates it from single-incretin therapies, enabling enhanced glucose homeostasis and energy balance in research settings.

In landmark trials like SURPASS (type 2 diabetes) and SURMOUNT (obesity/overweight), tirzepatide demonstrated dose-dependent efficacy. The 10mg weekly dose (a common maintenance level after titration) achieved mean HbA1c reductions of ~2.0–2.4% and body weight losses of ~19.5% (SURMOUNT-1) or ~12.8–13.4% (SURMOUNT-2 with T2D) over 72 weeks, outperforming comparators in many models.

Mechanism of Action

Tirzepatide activates incretin pathways to:

• Promote glucose-dependent insulin secretion from beta cells
• Suppress glucagon release
• Slow gastric emptying for prolonged satiety
• Reduce central appetite signals and caloric intake

This combined GIP/GLP-1 engagement improves insulin sensitivity, lowers fasting/postprandial glucose, and drives significant fat mass reduction, particularly visceral adipose tissue.

Key Research Findings and Benefits

Tirzepatide excels in metabolic investigations across multiple trials.

Glycemic Control in Type 2 Diabetes Models

SURPASS trials showed HbA1c reductions up to -2.4% at 10mg, with high proportions achieving targets below 7% or normoglycemic levels.

Weight Loss and Obesity Management

In SURMOUNT-1, the 10mg dose yielded ~19.5% average weight reduction over 72 weeks in non-diabetic obesity models. In SURMOUNT-2 (with T2D), ~12.8–13.4% loss was observed, with many participants achieving ≥5–20% reductions.

Cardiovascular and Metabolic Support

Studies indicate improvements in blood pressure, lipid profiles (reduced triglycerides/LDL, increased HDL), and potential risk mitigation for cardiometabolic events.

Research Applications

The 10mg vial supports:

• Type 2 diabetes mechanism and adjunct therapy studies
• Obesity and overweight experimental models
• Mid-range dose simulations, pharmacokinetics, and stability assessments
• Incretin synergy, metabolic syndrome, and dose-escalation research

Reconstitution example (lab protocols vary): Dissolve in 1–2 mL bacteriostatic water for concentrations enabling weekly dosing from initiation to maintenance levels.

Why Choose 99% Pure Tirzepatide 10mg?

Our tirzepatide 10mg offers ≥99% purity for reliable, reproducible results in peptide-receptor interactions, insulin dynamics, and long-term metabolic outcomes. Vacuum-sealed and third-party tested to minimize variables.

In summary, Tirzepatide 10mg is a versatile research tool for exploring dual-incretin therapies, weight loss mechanisms, diabetes control, appetite regulation, and metabolic health. Unlock its potential in your laboratory studies today.

Latest Testing:Link to Report